Vanda Pharmaceuticals Inc (VNDA)
6.05
-0.10
(-1.63%)
USD |
NASDAQ |
Jun 26, 10:23
Vanda Pharmaceuticals SG&A Expense (Annual): 112.88M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 112.88M |
| December 31, 2022 | 136.48M |
| December 31, 2021 | 124.05M |
| December 31, 2020 | 140.51M |
| December 31, 2019 | 129.74M |
| December 31, 2018 | 105.75M |
| December 31, 2017 | 123.84M |
| December 31, 2016 | 99.79M |
| December 31, 2015 | 84.53M |
| December 31, 2014 | 84.64M |
| Date | Value |
|---|---|
| December 31, 2013 | 25.08M |
| December 31, 2012 | 14.52M |
| December 31, 2011 | 11.49M |
| December 31, 2010 | 10.15M |
| December 31, 2009 | 23.72M |
| December 31, 2008 | 28.91M |
| December 31, 2007 | 32.80M |
| December 31, 2006 | 13.64M |
| December 31, 2005 | 7.396M |
| December 31, 2004 | 2.119M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
112.88M
Minimum
2023
140.51M
Maximum
2020
128.73M
Average
129.74M
Median
2019
SG&A Expense (Annual) Benchmarks
| ADMA Biologics Inc | 59.02M |
| INVO Bioscience Inc | 7.486M |
| Johnson & Johnson | 20.11B |
| Ligand Pharmaceuticals Inc | 52.79M |
| Sage Therapeutics Inc | 274.52M |